

**Supporting Information S2 Table. Region of Interest analyses without the medicated subjects.**

**Region of interest (ROIs) where GM volumes in female controls exceeded volumes in SCP patients after excluding subjects on medication.** The table presents GM volume in each group for ROIs where controls>patients (in the whole-brain) after removing the subjects who were on medication at the initial interview. The table also includes total GM volume for each group.

	<b>Controls (n=16)</b>	<b>Patients (n=13)</b>	<b>Reduction (%)</b>	
<b>Significant Cluster (from the whole-brain analyses)</b>	<b>(means±sd)</b>	<b>(means±sd)</b>	<b>Patients</b>	<b>p-value*</b>
<b>Cingulate Gyrus</b>	0.57±0.06	0.51±0.06	10.53	0.02
<b>Medial Prefrontal Cortex</b>	0.49±0.05	0.45±0.08	8.16	0.01
<b>Left Ventrolateral Prefrontal Cortex</b>	0.54±0.05	0.42±0.10	22.22	0.002
<b>Right Dorsolateral Prefrontal Cortex</b>	0.63±0.05	0.54±0.06	14.29	0.002
<b>Medial Orbitofrontal Cortex</b>	0.52±0.05	0.44±0.06	15.38	0.002
<b>Left Somatosensory Motor Cortex</b>	0.55±0.04	0.48±0.07	12.73	0.0007
<b>Left Angular Gyrus</b>	0.54±0.06	0.44±0.08	18.52	0.002
<b>Right Angular Gyrus</b>	0.61±0.03	0.52±0.06	14.75	0.0002
<b>Right Somatosensory Motor Cortex</b>	0.55±0.07	0.46±0.09	16.36	0.002
<b>Total GM Volume (ml)</b>	681.81±47.94	611.27±62.99	9.47	0.011

\*Analyses of covariance: ROI as dependent variable and group, age and IQ as covariates.